Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by Sisram Medical Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business update of the Group.

The Company is pleased to announce that new orders for the Group maintained strong market momentum in the third quarter of 2025, primarily driven by demand in China, South Korea, and Thailand. Alma Harmony, the Company's flagship multi-modal platform, recorded a solid increase in system orders during the quarter. Accordingly, the unaudited revenue of the Group for the quarter recorded healthy double-digit year-on-year growth.

Leveraging proactive market development and demand creation, the Group will continue to actively advance the deployment of Soprano family in the APAC region and the sales of Universkin by Alma in the U.S. market in the coming months of this year, while proceeding the commercial readiness for the upcoming DAXXIFY launch in Mainland China as planned.

This announcement is made based on a preliminary review of the unaudited operational data of the Group and the information currently available to the board of directors of the Company, and has not been reviewed or audited by the Group's auditors. The data do not constitute, represent or indicate the full picture of the Group's total revenue or financial performance, and the information contained in this announcement is provided for reference only.

Shareholders and potential investors of the Company are advised not to place undue reliance on the information disclosed herein and to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, 28 October, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*